Search Results - "CHANEL, Suzanne"

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia by Maslak, Peter G., Dao, Tao, Bernal, Yvette, Chanel, Suzanne M., Zhang, Rong, Frattini, Mark, Rosenblat, Todd, Jurcic, Joseph G., Brentjens, Renier J., Arcila, Maria E., Rampal, Raajit, Park, Jae H., Douer, Dan, Katz, Laura, Sarlis, Nicholas, Tallman, Martin S., Scheinberg, David A.

“…A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in…”
Get full text

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate by Berman, Ellin, Nicolaides, Maria, Maki, Robert G, Fleisher, Martin, Chanel, Suzanne, Scheu, Kelly, Wilson, Bri-Anne, Heller, Glenn, Sauter, Nicholas P

“…Hypophosphatemia, with associated changes in bone and mineral metabolism, developed in some patients with chronic myelogenous leukemia or gastrointestinal…”
Get full text

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms by Hobbs, Gabriela S, Hanasoge Somasundara, Amritha Varshini, Kleppe, Maria, Litvin, Rivka, Arcila, Maria, Ahn, Jihae, McKenney, Anna Sophia, Knapp, Kristina, Ptashkin, Ryan, Weinstein, Howard, Heinemann, Murk-Hein, Francis, Jasmine, Chanel, Suzanne, Berman, Ellin, Mauro, Michael, Tallman, Martin S, Heaney, Mark L, Levine, Ross L, Rampal, Raajit K

Get full text

Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide by CAMACHO, L. H, SOIGNET, S. L, CHANEL, S, HO, R, HELLER, G, SCHEINBERG, D. A, ELLISON, R, WARRELL, R. P

“…Arsenic trioxide, like all-trans-retinoic acid (RA), induces differentiation of acute promyelocytic leukemia (APL) cells in vivo. Treatment of APL patients…”
Get full text

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia by ROSENBLAT, Todd L, MCDEVITT, Michael R, LARSON, Steven M, SCHEINBERG, David A, JURCIC, Joseph G, MULFORD, Deborah A, PANDIT-TASKAR, Neeta, DIVGI, Chaitanya R, PANAGEAS, Katherine S, HEANEY, Mark L, CHANEL, Suzanne, MORGENSTERN, Alfred, SGOUROS, George

“…Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML)…”
Get full text

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies by WIEDER, Robert, NOVICK, Steven C, BONATE, Peter, WILLIAMS, Tom, SOIGNET, Steven, HOLLIS, Bruce W, BRYAN, Margarette, CHANEL, Suzanne M, OWUSU, Kate, CAMASTRA, Danielle, SAUNDERS, Tracie, PLINER, Lillian, HARRISON, Jonathan

“…Differentiation therapy is an alternative to chemotherapy with potentially less toxicity, improved quality of life, and survival. We conducted a phase I trial…”
Get full text

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia by Maslak, Peter G., Dao, Tao, Krug, Lee M., Chanel, Suzanne, Korontsvit, Tatyana, Zakhaleva, Victoria, Zhang, Ronghua, Wolchok, Jedd D., Yuan, Jianda, Pinilla-Ibarz, Javier, Berman, Ellin, Weiss, Mark, Jurcic, Joseph, Frattini, Mark G., Scheinberg, David A.

“…A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute…”
Get full text

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors by Berman, Ellin, Girotra, Monica, Cheng, Catherine, Chanel, Suzanne, Maki, Robert, Shelat, Meenakshi, Strauss, H. William, Fleisher, Martin, Heller, Glenn, Farooki, Azeez

“…Abstract Patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors (GIST) who take imatinib have abnormalities of bone metabolism…”
Get full text

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR) by Maslak, Peter George, Dao, Tao, Bernal, Yvette, Chanel, Suzanne M., Zhang, Rong, Frattini, Mark G, Rosenblat, Todd L., Jurcic, Joseph G, Rampal, Raajit, Park, Jae Hong, Douer, Dan, Katz, Laura, Gutierrez, Andres A, Tallman, Martin S., Scheinberg, David A.

“…Abstract only…”
Get full text

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR) by Rosenblat, Todd L., Frattini, Mark G., Chanel, Suzanne M., Dao, Tao, Bernal, Yvette, Jurcic, Joseph G., Zhang, Rhong, Simancek, Pamela, Tallman, Martin S, Scheinberg, David A., Maslak, Peter G.

“…Abstract 3624 WT1 is a transcription factor which has been implicated in leukemogenesis and has been used as a marker of minimal residual disease (MRD). We…”
Get full text

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST) by Berman, Ellin, Maki, Robert, Farooki, Azeez, Girotra, Monica, Chanel, Suzanne, Cheng, Catherine, Strauss, H. William, Fleisher, Martin

“…Abstract 2276 Imatinib (IM) inhibits several disease-associated tyrosine kinases, including BCR-ABL in CML, C-KIT in GIST, and PDGFR α and β in patients (pts)…”
Get full text

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML) by Jurcic, Joseph G., Rosenblat, Todd L., McDevitt, Michael R., Pandit-Taskar, Neeta, Carrasquillo, Jorge A., Chanel, Suzanne M., Zikaras, Kevin, Frattini, Mark G., Maslak, Peter G., Cicic, Dragan, Larson, Steven M., Scheinberg, David A.

“…Abstract 768 Lintuzumab, a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest activity against AML. To increase the antibody’s potency…”
Get full text

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies by Padmanabhan, Swaminathan, Kelly, Kevin R, Heaney, Mark, Hodges, Stephanie, Chanel, Suzanne, Frattini, Mark, Swords, Ronan, Bradley, Robert, Teofilovici, Florentina, DeAngelo, Daniel J

“…Abstract 2898 STA-9090 is a potent, second-generation, small-molecule Hsp90 inhibitor, with a chemical structure unrelated to the first-generation, ansamycin…”
Get full text

Sequential Cytarabine and a-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia by Rosenblat, Todd L, McDevitt, Michael R, Mulford, Deborah A, Pandit-Taskar, Neeta, Divgi, Chaitanya R, Panageas, Katherine S, Heaney, Mark L, Chanel, Suzanne, Morgenstern, Alfred, Sgouros, George, Larson, Steven M, Scheinberg, David A, Jurcic, Joseph G

“…PURPOSE: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid…”
Get full text

Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms by Maslak, Peter G., Krug, Lee, Chanel, Suzanne, Dao, Tao, James, Leonard, Tyson, Leslie, Bekele, Sara, Scheinberg, David A.

“…WT1 is a transcription factor over-expressed in several types of leukemia and solid tumors which has the potential to serve as a target for immune based…”
Get full text

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (213Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML) by Rosenblat, Todd, McDevitt, Michael R., Mulford, Deborah A., Pandit-Taskar, Neeta, Weiss, Mark A., Heaney, Mark L., Chanel, Suzanne, Morgenstern, Alfred, Larson, Steven M., Scheinberg, David A., Jurcic, Joseph G.

“…HuM195, a humanized anti-CD33 monoclonal antibody, targets myeloid leukemia cells and has single-agent activity against acute myeloid leukemia (AML). To…”
Get full text

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML) by Rosenblat, Todd L., McDevitt, Michael R., Pandit-Taskar, Neeta, Carrasquillo, Jorge A., Chanel, Suzanne, Frattini, Mark G., Larson, Steven M., Scheinberg, David A., Jurcic, Joseph G.

“…HuM195, a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest activity alone against AML. To increase the antibody's potency and allow…”
Get full text

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb by Berman, Ellin, Nicolaides, Maria, Sauter, Nicolas, Chanel, Suzanne, Wilson, Brianne, Fleisher, Martin

“…Imatinib is a tyrosine kinase that effectively inhibits the bcr-abl fusion protein in Philadelphia (Ph) chromosome positive CML and c-kit, which is…”
Get full text

Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) by Gupta, Seema, Weiss, Mark A., Jurcic, Joseph G., Chanel, Suzanne, Wilson, Bri-Anne, Biederman, Emily, Berman, Ellin, Scheinberg, David A., Maslak, Peter G.

“…Targeted modalities are playing a an increasing role in modern oncology. We have previously demonstrated that the unconjugated humanized anti-CD33 monoclonal…”
Get full text